BamSEC and AlphaSense Join Forces
Learn More

Syros Pharmaceuticals Inc.

NASDAQ: SYRS    
Share price (1/8/25): $0.21    
Market cap (1/8/25): $5.635 million
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.1
from 10-K 5 pages Description of Securities Registered Under Section 12 of the Exchange Act
12/34/56
EX-4.1
from 8-K 14 pages Syros Pharmaceuticals, Inc. [Form Of] Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-4.5
from S-3 8 pages Form of Subordinated Note
12/34/56
EX-4.4
from S-3 8 pages Form of Senior Note
12/34/56
EX-4.3
from S-3 61 pages Syros Pharmaceuticals, Inc. and Trustee Indenture Dated as of Subordinated Debt Securities
12/34/56
EX-4.2
from S-3 59 pages Syros Pharmaceuticals, Inc. and Trustee Indenture Dated as of Senior Debt Securities
12/34/56
EX-4
from 10-K 4 pages Description of Securities Registered Under Section 12 of the Exchange Act
12/34/56
EX-4.2
from 8-K 15 pages Syros Pharmaceuticals, Inc. [Form Of] Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-4.1
from 8-K 18 pages Syros Pharmaceuticals, Inc. Form of Warrant to Purchase Common Stock or Pre-Funded Warrants
12/34/56
EX-4.1
from 10-K 3 pages Description of Securities Registered Under Section 12 of the Exchange Act
12/34/56
EX-4.1
from 10-K 4 pages Description of Securities Registered Under Section 12 of the Exchange Act
12/34/56
EX-4.2
from 8-K 15 pages Syros Pharmaceuticals, Inc. Form of Pre-Funded Warrant to Purchase Common Stock
12/34/56
EX-4.1
from 8-K 18 pages Syros Pharmaceuticals, Inc. Form of Warrant to Purchase Common Stock or Pre-Funded Warrants
12/34/56
EX-4.5
from S-3 8 pages Form of Subordinated Note
12/34/56
EX-4.4
from S-3 8 pages Form of Senior Note
12/34/56
EX-4.3
from S-3 61 pages Syros Pharmaceuticals, Inc. and Trustee Indenture Dated as of Subordinated Debt Securities
12/34/56
EX-4.2
from S-3 59 pages Syros Pharmaceuticals, Inc. and Trustee Indenture Dated as of Senior Debt Securities
12/34/56
EX-4.1
from 10-K 4 pages Description of Securities Registered Under Section 12 of the Exchange Act
12/34/56
EX-4.2
from 8-K 2 pages Syros Pharmaceuticals, Inc. a Delaware Corporation Gerald E. Quirk, Secretary Nancy A. Simonian, Chief Executive Officer
12/34/56
EX-4.1
from 8-K 22 pages [Form of Warrant] Syros Pharmaceuticals, Inc. Class a Warrant to Purchase Common Stock
12/34/56